196 related articles for article (PubMed ID: 12721671)
1. [Glucocorticoid-induced insulin resistance and diabetes mellitus. Receptor-, postreceptor mechanisms, local cortisol action, and new aspects of antidiabetic therapy].
Meyer G; Badenhoop K
Med Klin (Munich); 2003 Apr; 98(5):266-70. PubMed ID: 12721671
[TBL] [Abstract][Full Text] [Related]
2. [Novel aspects in the mechanisms of steroid diabetes and the regulation of hepatic glucose production by insulin and steroids].
Barthel A; Scherbaum WA; Bornstein SR
Med Klin (Munich); 2003 Apr; 98(5):283-6. PubMed ID: 12721674
[TBL] [Abstract][Full Text] [Related]
3. Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.
Jacobson PB; von Geldern TW; Ohman L; Osterland M; Wang J; Zinker B; Wilcox D; Nguyen PT; Mika A; Fung S; Fey T; Goos-Nilsson A; Grynfarb M; Barkhem T; Marsh K; Beno DW; Nga-Nguyen B; Kym PR; Link JT; Tu N; Edgerton DS; Cherrington A; Efendic S; Lane BC; Opgenorth TJ
J Pharmacol Exp Ther; 2005 Jul; 314(1):191-200. PubMed ID: 15784656
[TBL] [Abstract][Full Text] [Related]
4. [Glucocorticoid-induced diabetes mellitus in gastrointestinal diseases].
Kern W; Stange EF; Fehm HL; Klein HH
Z Gastroenterol; 1999 Jun; Suppl 1():36-42. PubMed ID: 10444814
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance and its impact on the approach to therapy of type 2 diabetes.
Laakso M
Int J Clin Pract Suppl; 2001 Sep; (121):8-12. PubMed ID: 11594246
[TBL] [Abstract][Full Text] [Related]
6. Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.
Stefanović V; Antić S
Clin Lab; 2004; 50(5-6):271-8. PubMed ID: 15209435
[TBL] [Abstract][Full Text] [Related]
7. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
8. [New hypoglycemic drugs in treatment of diabetes type 2].
Sokup A; Swiatkowski M
Przegl Lek; 2000; 57(6):349-52. PubMed ID: 11107871
[TBL] [Abstract][Full Text] [Related]
9. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
10. Metformin and pioglitazone: Effectively treating insulin resistance.
Staels B
Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
[TBL] [Abstract][Full Text] [Related]
11. [Glucocorticoids and diabetes mellitus].
Vondra K; Hampl R
Vnitr Lek; 2006 May; 52(5):493-7. PubMed ID: 16771098
[TBL] [Abstract][Full Text] [Related]
12. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
13. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
14. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and the etiology of type 2 diabetes.
Sjöholm A; Nyström T
Diabetes Metab Res Rev; 2006; 22(1):4-10. PubMed ID: 15991254
[TBL] [Abstract][Full Text] [Related]
16. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?
van Raalte DH; Ouwens DM; Diamant M
Eur J Clin Invest; 2009 Feb; 39(2):81-93. PubMed ID: 19200161
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and costs of diabetes treated with insulin in France.
Detournay B; Raccah D; Cadilhac M; Eschwège E
Diabetes Metab; 2005 Jun; 31(3 Pt 2):3-18. PubMed ID: 16142041
[TBL] [Abstract][Full Text] [Related]
18. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
Leschke M
Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836
[TBL] [Abstract][Full Text] [Related]
19. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
